Clinical Trial Update: Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating bevacizumab (Avastin) plus erlotinib (Tarceva) in previously treated malignant mesothelioma. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED